Peptides / Weight and metabolic

Conjugate · 275 amino acids

Dulaglutide (Trulicity)

ApprovedNot banned in sport

Dulaglutide (Trulicity) is a GLP-1 receptor agonist fused to an antibody fragment, approved in the US and EU for type 2 diabetes and heart risk reduction. Studies in people tested it for blood sugar control and weight, and tracked stomach side effects. PepBank shows 1,605 results on dulaglutide from 279 studies in people, and 314 from animal and lab studies. The strongest evidence is a randomized trial in people. Data as of 2026-10-30.

Also known as Dulaglutide, LY-2189265, LY2189265, Trulicity

First 40 of 275 amino acids2 changed amino acids

Evidence level: Large trials in people1,605 of 1,919 results come from studies in people, including randomized trials.

Results in people

1,605

84% of 1,919 results

Results in animals

288

15% of 1,919 results

Results in lab cells

1% of 1,919 results

From computer models

0% of 1,919 results

Overview

Dulaglutide (Trulicity) at a glance

What it is	Conjugate, 275 amino acids
Approval	Approved in the US and EU (Trulicity)
In sport	Not listed as banned by WADA
Studies	418 studies with results. 318 of them gave dulaglutide, with 1,919 results. 1,605 in people288 in animals26 in lab cells
Best study in people	Randomized controlled trial with 13,165 people (2025)
Clinical trials	124 registered: 15 active or planned, 61 with posted results
Community use	A GLP-1 analog fused to an IgG4 Fc region, approved for type 2 diabetes and specified cardiovascular risk reduction.

The science

What is dulaglutide?

A GLP-1 analog fused to an IgG4 Fc region, approved for type 2 diabetes and specified cardiovascular risk reduction.

275

Amino acids in one chain

The history of dulaglutide

2008August
A registered trial of dulaglutide started (NCT00734474).
2010
The oldest paper on dulaglutide in PepBank is from 2010.

Dulaglutide (Trulicity) structure and chemistry

The key facts about the molecule. Long codes are in the closed section below.

Sequence, 275 amino acidsFrom the first amino acid to the last

H1G−EGT5FTS−DV10SSYL−E15−EQAA+K20−EFIAW25LV+KGG30GGGGG35SGGGG40SGGGG45SA−ES+K50YGPPC55PPCPA60P−EAAG65GPSVF70LFPP+K75P+K−DTL80MIS+RT85P−EVTC90VVV−DV95SQ−E−DP100−EVQFN105WYV−DG110V−EVHN115A+KT+KP120+R−E−EQF125NSTY+R130VVSVL135TVLHQ140−DWLNG145+K−EY+KC150+KVSN+K155GLPSS160I−E+KTI165S+KA+KG170QP+R−EP175QVYTL180PPSQ−E185−EMT+KN190QVSLT195CLV+KG200FYPS−D205IAV−EW210−ESNGQ215P−ENNY220+KTTPP225VL−DS−D230GSFFL235YS+RLT240V−D+KS+R245WQ−EGN250VFSCS255VMH−EA260LHNHY265TQ+KSL270SLSLG275

Darker means more water-repelling+ and − show charge in the body

Structure

Dulaglutide (Trulicity) is a conjugate of 275 amino acids, with no ring, 2 disulfide bonds, 2 changed amino acids.

CAS number

923950-08-7

Target

Glucagon-like peptide-1 receptor (gene GLP1R): agonistEvidence: official prescribing information

Development

Eli Lilly and Company. Highest phase: past the trial stage (see status).

Identifiers

UNII WTT295HSY5, DrugBank DB09045

See charge, composition and 3D structure on the Scientific page

The evidence

What dulaglutide studies show

Results grouped by what the studies measured. Each card shows where its results come from.

Large trials in people1,605 of 1,919 results come from studies in people, including randomized trials.

Blood sugar

564 results · 537 in people · 26 animal · 1 lab

In Japanese adults with diabetes, dulaglutide 1.5 mg reduced HbA1c more than 0.75 mg at week 26. Diabetes, obesity & metabolism, 2024

Top results

In Japanese adults with diabetes, dulaglutide 1.5 mg reduced HbA1c more than 0.75 mg at week 26. (Diabetes, obesity & metabolism, 2024)
In patients with diabetes, the change in disposition index did not differ between dulaglutide and trelagliptin. (Diabetology international, 2024)
In adults with diabetes, dulaglutide and its biosimilar produced similar blood sugar reductions at Week 24. (Journal of diabetes, 2025)

Weight and appetite

206 results · 199 in people · 7 animal

In women with PCOS, dulaglutide plus diet did not reduce visceral fat more than diet alone. Nutrients, 2023

Top results

In women with PCOS, dulaglutide plus diet did not reduce visceral fat more than diet alone. (Nutrients, 2023)
In healthy volunteers, food intake was identical with dulaglutide and placebo. (Endocrine, 2020)
In adults with diabetes and fatty liver, pancreatic fat did not differ significantly between dulaglutide and usual care. (Diabetologia, 2020)

Heart and blood vessels

86 results · 80 in people · 5 animal · 1 lab

In patients with diabetes and cardiovascular disease, tirzepatide was noninferior to dulaglutide for major cardiovascular events, without significant superiority. The New England journal of medicine, 2025

Top results

In patients with diabetes and cardiovascular disease, tirzepatide was noninferior to dulaglutide for major cardiovascular events, without significant superiority. (The New England journal of medicine, 2025)
Dulaglutide did not significantly reduce heart failure events compared with placebo. (European journal of heart failure, 2022)
In type 2 diabetes, dulaglutide 0.75 mg met noninferiority criteria versus placebo for systolic pressure changes. (Hypertension, 2014)

Kidneys and bladder

63 results · 56 in people · 7 animal

In patients with T2D and kidney disease, kidney filtration was higher with dulaglutide 1.5 mg than insulin glargine. The lancet. Diabetes & endocrinology, 2018

Top results

In patients with T2D and kidney disease, kidney filtration was higher with dulaglutide 1.5 mg than insulin glargine. (The lancet. Diabetes & endocrinology, 2018)
In people with diabetes and artery disease, dulaglutide had more combined kidney events than tirzepatide. (The lancet. Diabetes & endocrinology, 2026)
In T2D patients with cardiovascular disease or risk factors, dulaglutide reduced the combined kidney outcome compared with placebo. (Lancet, 2019)

Daily life and fitness

41 results · 40 in people · 1 animal

In people with diabetes receiving glargine, added dulaglutide improved weight self-perception more than placebo. Clinical therapeutics, 2017

Top results

In people with diabetes receiving glargine, added dulaglutide improved weight self-perception more than placebo. (Clinical therapeutics, 2017)
In patients with diabetes, treatment satisfaction scores decreased with continued dulaglutide but increased after switching to semaglutide. (Diabetes, obesity & metabolism, 2023)
In people with RRMS receiving natalizumab, exploratory analysis suggested improved walking speed with dulaglutide. (Neurology and therapy, 2026)

Cholesterol and blood fats

37 results · 35 in people · 2 animal

In Japanese patients with T2D, blood triglycerides did not differ significantly between dulaglutide and placebo. Diabetes therapy, 2019

Top results

In Japanese patients with T2D, blood triglycerides did not differ significantly between dulaglutide and placebo. (Diabetes therapy, 2019)
In Japanese patients with diabetes, dulaglutide did not significantly improve the blood fat ratio, whereas semaglutide did. (Diabetes, obesity & metabolism, 2023)
In patients with diabetes, total cholesterol fell with dulaglutide and changed in the other direction with placebo. (Lancet, 2018)

All 418 dulaglutide studies by area Open the Scientific page

Key dulaglutide studies

Studies in people come first, then studies in animals and in the lab.

People
Cardiovascular Outcomes with Tirzepatide versus Dulaglutide in Type 2 Diabetes
Nicholls et al. 2025 · The New England journal of medicine · 13,165 people · cited by 84
3 results
People
Cardiorenal Outcomes With Tirzepatide Compared With Dulaglutide in Patients With Diabetes and Cardiovascular Disease: A Post Hoc Analysis of the SURPASS-CVOT Randomized Clinical Trial
Nissen et al. 2026 · JAMA cardiology · 13,165 people · cited by 6
5 results
People
Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial
Gerstein et al. 2019 · Lancet (London, England) · 9,901 people · cited by 2,264
3 results
People
Similar cardiovascular outcomes in patients with diabetes and established or high risk for coronary vascular disease treated with dulaglutide with and without baseline metformin
Ferrannini et al. 2021 · European heart journal · 8,037 people · cited by 19
2 results
People
OR30-06 Assessment of Dulaglutide Safety in Older Patient Populations in Rewind
Konig et al. 2020 · Journal of the Endocrine Society · 5,256 people · cited by 0
4 results

All 418 Dulaglutide (Trulicity) studies

Dulaglutide clinical trials

ClinicalTrials.gov lists 124 trials of dulaglutide. 15 are active or planned, and 61 have posted results. PepBank does not show trial results.

Solid bars are dates that happened. Hatched bars are planned dates. Data from ClinicalTrials.gov.

A Study of Tirzepatide (LY3298176) Compared With Dulaglutide on Major Cardiovascular Events in Participants With Type 2 Diabetes

Phase 3completed13,299 people

Researching Cardiovascular Events With a Weekly Incretin in Diabetes (REWIND)

Phase 3completed9,901 people

A Study of the Efficacy and Safety of Dulaglutide (LY2189265) in Participants With Type 2 Diabetes

Phase 3completed1,842 people

All 81 Dulaglutide (Trulicity) trials

Status and safety

Is dulaglutide approved?

FDA

United States

Approved

An approved medicine contains it.

EMA

European Union

Approved

An approved medicine contains it.

WADA

Sport

Not banned

Not on the 2026 Prohibited List.

Yes. Approved in the US and EU (Trulicity). The FDA label for Trulicity says: “A GLP-1 analog fused to an IgG4 Fc region, approved for type 2 diabetes and specified cardiovascular risk reduction” Not listed as banned by WADA.

Laws and labels change, so check the regulator for the current status.

Dulaglutide side effects and safety

PepBank has 488 safety results from studies of dulaglutide. 445 of them come from studies in people.

Safety results from studies (488)

In older REWIND patients, death or severe low blood sugar occurred in 15.2% with dulaglutide versus 16.1% with placebo. (Journal of the Endocrine Society, 2020)
In Japanese patients with diabetes, 53 of 65 dulaglutide recipients had adverse events. (The lancet. Diabetes & endocrinology, 2020)
In Japanese patients with T2D, adverse events were slightly more frequent with dulaglutide than placebo. (Diabetes therapy, 2019)
In people with diabetes and artery disease, nausea occurred less often with dulaglutide than tirzepatide. (The lancet. Diabetes & endocrinology, 2026)
In both Japanese patient subgroups, gastrointestinal side effects were more frequent with dulaglutide than glargine. (Endocrine journal, 2017)
In Japanese patients receiving dulaglutide, digestive symptoms were the most common side effects. (Diabetes therapy, 2020)
In patients with diabetes and heart disease, dulaglutide caused fewer digestive side effects than tirzepatide. (JAMA cardiology, 2026)
In T2D patients with cardiovascular disease or risk factors, deaths did not differ significantly between dulaglutide and placebo. (Lancet, 2019)
In patients with T2D, adverse-event discontinuation was similar with dulaglutide 3 mg and 1.5 mg. (Journal of the Endocrine Society, 2020)
In mainly Asian patients with T2DM, fewer had low blood sugar with dulaglutide than glargine. (Diabetes, obesity & metabolism, 2019)
In East-Asian patients with T2D, dulaglutide had lower low-blood-sugar rates than glimepiride. (Diabetes, obesity & metabolism, 2018)
In Chinese T2DM patients, low blood sugar occurred less often with dulaglutide than glargine. (Diabetes therapy, 2019)
In patients with diabetes, digestive adverse events were the most common reason for stopping dulaglutide treatment. (The lancet. Diabetes & endocrinology, 2018)
In adults with diabetes, common side effects in both groups included reduced appetite, diarrhea, nausea, vomiting, high uric acid and infections. (Journal of diabetes, 2025)
In Chinese patients with diabetes, low blood sugar affected fewer patients with dulaglutide 0.75 mg than glimepiride. (Journal of diabetes investigation, 2020)
In Japanese patients with type 2 diabetes, low blood sugar was less common with dulaglutide than glargine. (Diabetes, obesity & metabolism, 2015)
In people with diabetes, hypoglycaemia rates did not differ significantly between dulaglutide and placebo added to glargine. (Diabetes, obesity & metabolism, 2017)
Low blood sugar occurred more often with dulaglutide than placebo during glimepiride treatment. (Diabetes, obesity & metabolism, 2016)
One patient receiving dulaglutide 1·5 mg died from septicaemia after randomisation. (Lancet, 2015)
In patients with diabetes, low blood sugar occurred at similar rates with dulaglutide or placebo alongside insulin. (Diabetes, obesity & metabolism, 2023)
In adults with diabetes, serious adverse events occurred in 10 people receiving dulaglutide and 10 receiving tirzepatide. (Annals of internal medicine, 2025)
In patients with type 2 diabetes, low blood sugar was uncommon but more frequent with LY than placebo during the initial 4 weeks. (Diabetes, obesity & metabolism, 2011)
In adult smokers, gastrointestinal symptoms were numerically more frequent with dulaglutide than placebo. (EClinicalMedicine, 2023)
During follow-up, treatment-unrelated adverse events numbered 51 with dulaglutide and 48 with placebo. (EClinicalMedicine, 2024)

See every safety result on the Scientific page

Doses studied (40 shown)

The doses that these studies used. They are not recommendations.

Dose as reported	Class	Species	Route	Duration	Design	Source
1.5 mg weekly	Human	human	subcutaneous	Not reported	Randomized trial in people · n = 13,165	Nicholls 2025
1.5 mg weekly	Human	human	subcutaneous	median treatment duration 46.9 months	Randomized trial in people · n = 13,165	Nissen 2026
1.5 mg weekly	Human	human	subcutaneous	Median follow-up 5.4 years	Randomized trial in people · n = 9,901	Gerstein 2019
1.5 mg weekly	Human	human	subcutaneous	Not reported	Randomized trial in people · n = 8,037	Ferrannini 2021
1.5 mg once weekly	Human	human	Not reported	26 weeks	Randomized trial in people · n = 591	Morioka 2024
1.5 mg once weekly	Human	human	subcutaneous	24 weeks	Randomized trial in people · n = 440	Liu 2025
1·5 mg once weekly	Human	human	subcutaneous	32 weeks	Randomized trial in people · n = 415	He 2025
1.5 mg once weekly	Human	human	Not reported	26 weeks	Randomized trial in people · n = 378	Shi 2020
0.75 mg weekly	Human	human	Not reported	26 weeks	Randomized trial in people · n = 361	Araki 2015
1.5 mg weekly	Human	human	subcutaneous	28 weeks	Randomized trial in people · n = 300	Pozzilli 2017
1.5 mg once weekly	Human	human	Not reported	28 weeks	Randomized trial in people · n = 291	Wang 2023
4.5 mg or maximum tolerated dose	Human	human	Not reported	40 weeks	Randomized trial in people · n = 282	Billings 2025
1.5 mg once weekly	Human	human	subcutaneous	12 weeks	Randomized trial in people · n = 255	Lengsfeld 2023
1.5 mg once weekly	Human	human	subcutaneous	12 weeks	Randomized trial in people · n = 255	Lüthi 2024
1.5 mg weekly	Human	human	subcutaneous	12 weeks	Randomized trial in people · n = 255	2022
1.5 mg weekly	Human	human	Not reported	26 weeks	Randomized trial in people · n = 183	Tuttle 2018
0.75 mg weekly	Human	human	Not reported	26 weeks	Randomized trial in people · n = 180	Tuttle 2018
1.5 mg	Human	human	subcutaneous	20 weeks	Randomized trial in people · n = 101	Zhang 2024
0.75 mg weekly	Human	human	subcutaneous	24 weeks	Randomized trial in people · n = 80	Adly 2026
0.75 mg single dose	Human	human	abdominal subcutaneous	Not reported	Randomized trial in people · n = 68	Gao 2024
0.75 mg weekly	Human	human	subcutaneous	52 weeks	Randomized trial in people · n = 65	Yabe 2020
0.75 mg/week	Human	human	Not reported	24 weeks	Randomized trial in people · n = 63	Takahashi 2023
0.75 mg/week	Human	human	Not reported	24 weeks	Randomized trial in people · n = 48	Kondo 2024
1·5 mg	Human	human	injection	24 weeks	Randomized trial in people · n = 46	Rosenstock 2023
1.5 mg weekly	Human	human	Not reported	3 weeks	Randomized trial in people · n = 34	Winzeler 2021
1.5 mg weekly	Human	human	Not reported	3 weeks	Randomized trial in people · n = 34	Winzeler 2021
0.75 mg once weekly	Human	human	subcutaneous	12 months	Randomized trial in people · n = 28	Šiarnik 2026
0.75 mg/week (uptitrated at week 4 if tolerated)	Human	human	Not reported	12 weeks	Randomized trial in people · n = 24	Jun 2026
1.5 mg once weekly	Human	human	subcutaneous	3 weeks	Randomized trial in people · n = 20	Winzeler 2020
1.5 mg	Human	human	subcutaneous	Not reported	Randomized trial in people · n = 20	de 2017
0.75 mg once weekly	Human	human	Not reported	4 weeks	Randomized trial in people · n = 12	Inoue 2019
1.5 mg weekly	Human	human	subcutaneous	26 weeks	Randomized trial in people	Frias 2018
0.75 mg weekly	Human	human	subcutaneous	40 weeks	Randomized trial in people	Pratley 2018
1.5 mg weekly	Human	human	subcutaneous	40 weeks	Randomized trial in people	Pratley 2018
1.5 mg weekly	Human	human	subcutaneous	26 weeks	Randomized trial in people	Umpierrez 2014
1.5 mg weekly	Human	human	Not reported	52 weeks	Randomized trial in people	Giorgino 2015
1·5 mg once weekly	Human	human	Not reported	26 weeks	Randomized trial in people	Blonde 2015
0·75 mg once weekly	Human	human	Not reported	26 weeks	Randomized trial in people	Blonde 2015
4.5 mg weekly	Human	human	Not reported	36 weeks	Randomized trial in people	Frias 2021
3.0 mg weekly	Human	human	Not reported	36 weeks	Randomized trial in people	Frias 2021

From the community

How people use it

What people report online. It comes from forums and guides, not from studies.

Community-reported. Not tested in trials.

The official US label describes prescription use. These regimens are label information and are not community practice.

Reported routines and cautions

What people use it for

A GLP-1 analog fused to an IgG4 Fc region, approved for type 2 diabetes and specified cardiovascular risk reduction.S1

Reported regimens

Regimens that community sources report for Dulaglutide. Community-reported, not tested in trials.
Context	Route	Amount	How often	How long	Agreement	Sources
Adult type 2 diabetes starting doseOfficial label dosing of an approved product	subcutaneous injection	0.75 mg per dose	once weekly	Not stated	Official US prescribing information.	S1
Adult type 2 diabetes dose increasesOfficial label dosing of an approved product	subcutaneous injection	1.5 to 4.5 mg per dose	once weekly	Not stated	Official US prescribing information.	S1

Cautions

The boxed warning concerns thyroid C-cell tumors. The label also warns about pancreatitis and serious gastrointestinal adverse reactions.S1

Community sources

S1US Dulaglutide prescribing information (opens in a new tab)dailymed.nlm.nih.gov

Gaps

No additional community use met the source and quote requirements. The record does not reproduce every administration instruction.

Questions and more

Ask a question about dulaglutide

The answer links to every study it uses.

What does the evidence say about dulaglutide?Is dulaglutide tested in people?Compare with Liraglutide Compare with Semaglutide

Sources

Database: PepBank data for dulaglutide (data version 308560)
Regulator: FDA status record
Regulator: EMA status record
Regulator: WADA status record
Trial registry: ClinicalTrials.gov
Community: community sources (forums and guides), as summarized in the PepBank community file

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

PepBank is a research reference. Talk to a doctor before you use any peptide.

Ask your AI about dulaglutide

Dulaglutide (Trulicity)

ApprovedNot banned in sport

Also known as Dulaglutide, LY-2189265, LY2189265, Trulicity

What it is

Conjugate, 275 amino acids

Approval

Approved in the US and EU (Trulicity)

In sport

Not listed as banned by WADA

Studies

418 studies with results. 318 of them gave dulaglutide, with 1,919 results.
1,605 in people288 in animals26 in lab cells

Best study in people

Randomized controlled trial with 13,165 people (2025)

Clinical trials

124 registered: 15 active or planned, 61 with posted results

Community use

A GLP-1 analog fused to an IgG4 Fc region, approved for type 2 diabetes and specified cardiovascular risk reduction.

Dose as reported

Class

Species

Route

Duration

Design

Source

1.5 mg weekly

Human

human

subcutaneous

Not reported

Randomized trial in people · n = 13,165

Nicholls 2025

1.5 mg weekly

Human

human

subcutaneous

median treatment duration 46.9 months

Randomized trial in people · n = 13,165

Nissen 2026

1.5 mg weekly

Human

human

subcutaneous

Median follow-up 5.4 years

Randomized trial in people · n = 9,901

Gerstein 2019

1.5 mg weekly

Human

human

subcutaneous

Not reported

Randomized trial in people · n = 8,037

Ferrannini 2021

1.5 mg once weekly

Human

human

Not reported

26 weeks

Randomized trial in people · n = 591

Morioka 2024

1.5 mg once weekly

Human

human

subcutaneous

24 weeks

Randomized trial in people · n = 440

Liu 2025

1·5 mg once weekly

Human

human

subcutaneous

32 weeks

Randomized trial in people · n = 415

He 2025

1.5 mg once weekly

Human

human

Not reported

26 weeks

Randomized trial in people · n = 378

Shi 2020

0.75 mg weekly

Human

human

Not reported

26 weeks

Randomized trial in people · n = 361

Araki 2015

1.5 mg weekly

Human

human

subcutaneous

28 weeks

Randomized trial in people · n = 300

Pozzilli 2017

1.5 mg once weekly

Human

human

Not reported

28 weeks

Randomized trial in people · n = 291

Wang 2023

4.5 mg or maximum tolerated dose

Human

human

Not reported

40 weeks

Randomized trial in people · n = 282

Billings 2025

1.5 mg once weekly

Human

human

subcutaneous

12 weeks

Randomized trial in people · n = 255

Lengsfeld 2023

1.5 mg once weekly

Human

human

subcutaneous

12 weeks

Randomized trial in people · n = 255

Lüthi 2024

1.5 mg weekly

Human

human

subcutaneous

12 weeks

Randomized trial in people · n = 255

2022

1.5 mg weekly

Human

human

Not reported

26 weeks

Randomized trial in people · n = 183

Tuttle 2018

0.75 mg weekly

Human

human

Not reported

26 weeks

Randomized trial in people · n = 180

Tuttle 2018

1.5 mg

Human

human

subcutaneous

20 weeks

Randomized trial in people · n = 101

Zhang 2024

0.75 mg weekly

Human

human

subcutaneous

24 weeks

Randomized trial in people · n = 80

Adly 2026

0.75 mg single dose

Human

human

abdominal subcutaneous

Not reported

Randomized trial in people · n = 68

Gao 2024

0.75 mg weekly

Human

human

subcutaneous

52 weeks

Randomized trial in people · n = 65

Yabe 2020

0.75 mg/week

Human

human

Not reported

24 weeks

Randomized trial in people · n = 63

Takahashi 2023

0.75 mg/week

Human

human

Not reported

24 weeks

Randomized trial in people · n = 48

Kondo 2024

1·5 mg

Human

human

injection

24 weeks

Randomized trial in people · n = 46

Rosenstock 2023

1.5 mg weekly

Human

human

Not reported

3 weeks

Randomized trial in people · n = 34

Winzeler 2021

1.5 mg weekly

Human

human

Not reported

3 weeks

Randomized trial in people · n = 34

Winzeler 2021

0.75 mg once weekly

Human

human

subcutaneous

12 months

Randomized trial in people · n = 28

Šiarnik 2026

0.75 mg/week (uptitrated at week 4 if tolerated)

Human

human

Not reported

12 weeks

Randomized trial in people · n = 24

Jun 2026

1.5 mg once weekly

Human

human

subcutaneous

3 weeks

Randomized trial in people · n = 20

Winzeler 2020

1.5 mg

Human

human

subcutaneous

Not reported

Randomized trial in people · n = 20

de 2017

0.75 mg once weekly

Human

human

Not reported

4 weeks

Randomized trial in people · n = 12

Inoue 2019

1.5 mg weekly

Human

human

subcutaneous

26 weeks

Randomized trial in people

Frias 2018

0.75 mg weekly

Human

human

subcutaneous

40 weeks

Randomized trial in people

Pratley 2018

1.5 mg weekly

Human

human

subcutaneous

40 weeks

Randomized trial in people

Pratley 2018

1.5 mg weekly

Human

human

subcutaneous

26 weeks

Randomized trial in people

Umpierrez 2014

1.5 mg weekly

Human

human

Not reported

52 weeks

Randomized trial in people

Giorgino 2015

1·5 mg once weekly

Human

human

Not reported

26 weeks

Randomized trial in people

Blonde 2015

0·75 mg once weekly

Human

human

Not reported

26 weeks

Randomized trial in people

Blonde 2015

4.5 mg weekly

Human

human

Not reported

36 weeks

Randomized trial in people

Frias 2021

3.0 mg weekly

Human

human

Not reported

36 weeks

Randomized trial in people

Frias 2021

Context

Route

Amount

How often

How long

Agreement

Sources

Adult type 2 diabetes starting doseOfficial label dosing of an approved product

subcutaneous injection

0.75 mg per dose

once weekly

Not stated

Official US prescribing information.

Adult type 2 diabetes dose increasesOfficial label dosing of an approved product

subcutaneous injection

1.5 to 4.5 mg per dose

once weekly

Not stated

Official US prescribing information.

Dulaglutide (Trulicity)

Dulaglutide (Trulicity) at a glance

What is dulaglutide?

The history of dulaglutide

Dulaglutide (Trulicity) structure and chemistry

What dulaglutide studies show

Blood sugar

Weight and appetite

Heart and blood vessels

Kidneys and bladder

Daily life and fitness

Cholesterol and blood fats

Key dulaglutide studies

Dulaglutide clinical trials

Is dulaglutide approved?

Dulaglutide side effects and safety

How people use it

What people use it for

Reported regimens

Cautions

Community sources

Ask a question about dulaglutide

Related peptides

Dulaglutide vs tirzepatide

Sources

Dulaglutide (Trulicity)

Dulaglutide (Trulicity) at a glance

What is dulaglutide?

The history of dulaglutide

Dulaglutide (Trulicity) structure and chemistry

What dulaglutide studies show

Blood sugar

Weight and appetite

Heart and blood vessels

Kidneys and bladder

Daily life and fitness

Cholesterol and blood fats

Key dulaglutide studies

Dulaglutide clinical trials

Is dulaglutide approved?

Dulaglutide side effects and safety

How people use it

What people use it for

Reported regimens

Cautions

Community sources

Ask a question about dulaglutide

Related peptides

Dulaglutide vs tirzepatide

Sources